Member Info for neilin62

"love how peoples opinions are changing.....) err pretty much just Joe from what i see, and to be fair his history does seem to suggest he has a run of bad investments. (no offence Joe)

re the reference to the news in Sept/Oct - read my post (30/05/23) again. I quite clearly said i thought there could be a possible timeline due to there being a number of coincidences.

Conduit merger completing - it did

Kit ready for clinical trials - it is

Platform ready to go - it is

Rns to say we are working in partnership with Bio-Techne not big enough news for you?

You question my research, i told you about the licensing deals i thought would come - they have

i told you about the clinical trials being previously carried out so we can now submit in retrospective evidence.

I told you many multiple things that are correct.

I told you about us being officially stated as being "one of the key players" in Berkshire Hathaways newswire.

If you did any research you would now know all about the latest reports such as:

Companion Diagnostics recent developments

Specifically Section 6.27 and 6.41 referencing Bio-Techne & Cizzle

Market forecasts for Immuno-Oncology diagnostics

Specifically Sections 7.25 and 7.39 again referencing Bio-Techne and Cizzles part

Liquid Biopsy recent developments

Specifically sections 5.20 - Corepath & Cizzle

Specifically Section 5.31 -Who Bio-techne have just aquired.

Specifically sections 6.35 and 6.24 referencing Bio-Techne and Cizzle

At least i try to share my research, whereas yours is just "boo-hoo my shares are down from the IPO"

My research had made me confident enough to invest a SIGNIFICANT amount while some talk their investment down.

I am not a big fan of "i told you so" but WHEN, and not IF this comes good, you will be my first message.

PS research well known phrases.

It is "smoke and mirrors", not "smoke and daggers"

Neil

There have been a number of posts comparing Vela and Ciz with the PUT options, and opinion that they have a much better deal than us.

I may be wrong, but even if we sold everything today we would still be in profit.

We paid £1.88m + premium of £120k giving a total outlay of £2m

However, we only actually paid £120k in cash

The remainder was in shares.

If we sold our shares today at $6.30 (prices are based on when i did the sums so could be different, but the principle remains the same) we would have £2,042,000 at exchange rate of $1.22 / £1

Vela paid £1.25m in cash, £1.1m in shares, and a premium of £400k

If my maths is correct, IF they exercise the option, they will receive 486,720 shares

Using the formula above that i used for CIZ, then their return would be a LOSS of 236,610

I say IF they exercise the option, because it is notable that their BOD have not RNS'd the option has been exercised. I believe that they may very well be considering that their best option is to see if the sp does increase, or just let the option lapse with the loss of the premium.

Even though on the face of it, it looks like we have a bad deal, we have done far better than Vela.

Neil

I don't know where some are getting the idea about delaying the exercise date for a better price, or 10 day VWAP making a difference?

The option was made at a strike price of $10 per share so it doesn't make any difference when we exercised it, today, next week, it would still be $10 and 395,460 shares

Also, we haven't "lost" anything. Conduit share price is down yes, but it's not as if we have sold them all this morning and got less for them than we were expecting. They are CURRENTLY trading at a lower value that's all.

The BOD will decide when, and how to deal with the share when they deem it appropiate to do so.

Neil

Dawn Coverley has been busy lately.

Might explain the vacancy for the position of technician i posted about 3 weeks ago.

22-09-2023 published a new paper into a study on epigenetic instability using CIZ1

(epigenetics is the study of how cells control gene activity without modifying the DNA sequence)

The study was primarily aimed at breast cancer, - keywords were "striking and consistent in breast tumours" - but it has also thrown up some interesting results on other cancers - bladder, colon, thyroid -

Seems she is excited about a strategy to suppress CIZ DNF's, the aim of which is to dampen pre-genetic instability in order to promote cancer AVOIDANCE. So now we are not only looking at early detection of cancer, but the possibility of actually being able to avoid it in the first place!

Neil

With the greatest respect, 50 / 50 is rubbish.

We have spent years (20+) developing this technology and have already demonstrated success on Western Blot technique before developing a sandwich assay, The technology has been proved to work through numerous clinical trials previous. . The stage we are at now is the trials to demonstrate that the tests results are repeatable, comparing to retrospective data, using the automated platform as this is required for high volume/throughput for hospital use.

So chance of failure? in my opinion very small to almost non existant.

Don't forget this is a DIAGNOSTIC test, not a drug, so the level of clinical trials is nowhere near as onerous. This is why we are going down the LDT route via an accredited laboratory.

In US we will be going for FDA CLEARANCE - NOT APPROVAL. 2 very different things.

and yes, i can guarantee that the NHS are very aware of Cizzle Biotech

Antelope, it is good that you have questioned your thoughts, but at the same time, don't ever rely too much on what you are told here. - and that includes me!

All i can say is i know what i have researched, i know what has evolved, and i am more than happy with my investment.

Best regards

Neil

The query as to Allan being invited to China........

Some of you may be unaware of his involvement regarding China.

Allan previously held the position of SPECIALIST ADVISOR ON CHINA TO THE DEPARTMENT OF INTERNATIONAL TRADE

so he is most certainly very well connected with high ranking Chinese officials.

Anybody still wondering why there is a connection with us and China?

Best regards

Neil

Morning Vincent Vega

My opinion on yesterdays RNS is that it;s a very, very good one

Why do i think this?

Well we knew that the development if the platform has been the subject of much speculation/news lately, and whilst i didn't expect Allan to be in his shed making such a machine, i didn't expect this development and evaluation to be with such a high profile /diverse company. I expected it to be with just a developer.

Now this COULD be a massive boost to us, because there is every possibility of a reciprocal agreement between us.

A long time back, i said that one of the revenue streams we would be pursuing would be the licensing of our product for others to use with their products.

Given that Bio-Techne consider the platform to be "ideal for supporting an assay of this nature" it is not beyond the realms of possibility that they could offer the platform and, under licence to us, CIZ1b assay alongside, to their customers.

Also, their position in the market opens up further entries into the market, and puts us in the face of more possible customers.

With Bio-Techne, Corepath, and Benhke in our corner, i think we are building quite a position.

On the subject of revenue streams, personally i think that too much emphasis is being placed by some on the Murphy /Conduit option.

Whilst this will be a very welcome boost, it was always a one off "bonus" to the main focus of the company, and there will be other opportunities to create revenue along the way.

Best regards

Neil

Widglide,

You think 250,000 is a "large " trade?

Jeez, you would have a frickin coronary if i started selling then!

You say no substantial progress has been made. I beg to differ. There has been an immense amount of progress. It just hasn't transformed into the share price rise that you want - --yet.

A massive development was the breakthrough in the platform enabling automated testing which is required for hospital environment.

We are now at the stage of scaling up production of the antibodies / reagents from research levels to commercial levels.

You might have missed the point Allan made that research was expanded so we now have a library of antibodies to develop into other projects.

You might also have missed that we are funding the placement of a technician at York University (interviews will be held on 15th sept) to assist Dawn Covereley in the progress of CIZ!B assay development.

Or that Allan will be in China in coming days, and if i am correct in my thiinking , he will be back in US sooner than later.

If my memory serves me, i said that i believed that this year would be the start of something big for us. Well there's still 4 months left of this year , so far from "oh boy was he wrong", lets see what happens shall we?

Pharma development NEVER conforms to fixed timescales .

There is a reason that the BOD took up the opportunity to get more money into the company with the placing. - to ramp up production in anticipation of the trials, to enable commercialisation, advance projects, develop new ones., and in particular, bringing forward development of the lateral flow kit, which i believe will see news in the near future. Sorry i can't give you dates though.

Neil

My understanding is that no replacement RNS is required, since the one published on 10th August is correct.

(if badly worded)

The linkedin reference was the incorrect one, and as LB say's has now been corrected to align with RNS.

It would have been far better to have stated "the company are now engaged in the design of clinical trials" which is much clearer.

Still, heading in the right direction, even if not what we hoped it meant re past/present tense.

Neil

Hi ROTP

You will no doubt have noticed that i have never stated a share price. Reason being is that i don't agree with posts that make statements like " i can see 3p/4p/ etc by the end of the day/week, as it is based on nothing more than pure guesswork, As we all see from the share price, it never behaves how you would think it would - especially following any news. Also because there are a number of holders that have simply fallen out of favour with the length of time it is taking, and see potential quicker gains elsewhere. Subsequently, on every decent rise, you will see sells by some simply wanting out.

All i will say, like i have said before - i am not interested in a few thousand quid return on my investment. Having said that, i always say do not base any intention to invest on what i say.

My positivity comes from over 2 years of researching anything and everything i can about the company, the technology, and the directors/people involved, competition, and market. I have spoken with oncology professors, had emails with clinical leads.

I like directors that take a lesser salary than industry norm.

I like the lifetime of expertise that Dr Coverley brings .

I like the sector that we are trying to conquer. Saving lives.

We are in a sector where there is an immediate and currently, unmet need for our test kits. Yes there are others trying to do the same, but from what i can see, they aren't in the same league as what our kit will do. - Detect cancer at the very earliest stage.

Diversifying the technology into detection of other cancers.

The market is immense when we get this commercialized. Iccam (China) and Behnke (USA) are footing the bill for getting the kits to market in their countries and would not be doing so if they thought for one minute that they would fail, and we will be selling them our reagents, mabs, etc in order to do so. Commercial tie ups with SGSC etc, the upcoming PUT option with Conduit/Murphy ...all positive.

And to put the icing on the cake, we are looking to develop our kits to lateral flow design similar to the home covid tests. Try and imagine how many people would be prepared to purchase a kit that gives them results that do not involve CT scans, high probability of false positives, surgical biopsies.

Neil

Evening Paname

Sorry for the late reply, but i have only just got in from work.

If i can respond first to a couple of things...

OAKP20 - you seem to have a problem with me, so lets sort it out. Your post last night "what, iv'e had an email but can't tell you" , and previous posts along the same line.

From day 1 i have only ever posted whatever information i have been given, and never held anything back. Can you please advise where i have ever said anything like i have information but not telling you?

If you can then i will be the first to apologise. If you can't, then i trust you will afford me the same courtesy? I have a serious amount of money invested in this company, and i want to know as much as possible about my investment. Because of this,

I have said that i have asked a lot of questions of the board on numerous occasions. Some of the questions they answered, and i gave responses on here. Some of the questions they advised that they were unable to answer, as the required response would need to be RSN'd, so i could not post anything other than i had been told. i have never said that i have information that i won't pass on.

Not sure about your comment today regarding Paname and "someone's got a new username" whether that was aimed at me or Paname, but i can give you my word that i am not him (or her) and he/she is not me. I think my posting history would show my honestly.

Lovelyboy- evening mate. i noticed the subtle differences between the RNS and the tweet, but i was more concentrated on the lines" We are now ENGAGED in clinical trials.... "against the line ".....to COMMENCE clinical trials......" Along with your thoughts, there is a very distinct difference, which is a bit disappointing that they can't communicate a clear, precise message. It could very easily be that the clinical trials are part of the preparation market launch and clinical trials for NHS

Either way, it certainly seems good news in that everything is progressing, and heading in the right direction, and a step nearer commercialisation.

A line i picked up on, and not sure if anyone else attached any relevance to, was regarding the approvals.

Normal mention of CE, UKCA, and FDA, but this RNS includes the words ".......AND WITH THE APPROPRIATE REGULATORY GROUPS ELSEWHERE IN THE WORLD "

I posted in a previous post about possible market extending to Canada and Indo/Asia.

Paname - thank you for your post. As you may see from the above, i am very positive on this company, and the news today just reaffirms my belief that we are going from strength to strength ( i do not take much notice of the day to day share price as it has no correlation to the company that we will be)

Neil

Because you weren't there!

Neil

Joe_Bloggs

Have you raised your concerns with the BOD?

Did you ask them anything at the AGM this morning?

No, i did'nt think so. Stop being a coward and ask them straight.

Widglide, yes, SP is down, and while it is not up to me to justify it to you, or anyone else, am i disappointed? A bit. But as i have said numerous times, i am not interested in the day to day price. I am invested in what this will become.

Neil

Widglide-

Tell us about your understanding of the role AI learning algorithms will have in conjunction with our test? Or the relevance of Bioluminescence detection?

Or the possibility of partnering with a drug company with nanobot technology in order to deliver targeted treatment to the cancer cells?

Anybody can sit there saying this company is shlt. Lets have something positive.

formerlyeasyp-

Yes i know about first mover advantage, but the 18 year old report kind of answered your own question there.

For example how come Betamax was marketed 2 years before VHS, (showing my age now!) had 100% of the market, was a far superior product, yet got wiped out by VHS?

Joe-Bloggs-

Because we are waiting for you to sell up!

Neil

I really don't get this fixation about "not being first" or "too late to the party" or "missed the boat"

Do people really think that the market isn't big enough for more than one player?

Name me another sector in which one company controls the entire 100% of the market.

An extension of that thinking is that we should all be driving Fords, since Henry Ford was first to the mass market ( i know....Benz patented the first automobile before anyone says it).

Neil

So...

1. Will you apologise when it is commercialsed? Yes or No?

2. You are so convinced it's a scam, so when will you sell up to recover whatever you can?

Neil

Widglide

Will you come back here and apologise for that comment when the test is commercialised?

Neil

I do not put "a different spin on it everytime"

I post my HONEST opinion at the time based on what information i have from wherever i get it.

That said, why don't some of you try putting your hands in your pockets and paying subscriptions to find out information?

Or picking the phone up and speaking to the BOD or IFC?

Or emailing the company?

How many of you have actually spoken with health professionals in the NHS?

Have any of you spoken with any Professors of Oncology ?

No thought not.

I don't NEED or HAVE to do any of this, i am only trying to help people understand their investment.

Right, now i have got that off my chest, a few responses:

1. It was acknowledged that yes, the RNS could have said more.

2. One of the questions i did ask, was about the issue of the "fully funded" comment as that did concern me. However, the "fully funded until 2024" was based on the current work in progress to develop the test. It was not including future work, which is what the POC test is. You can shoot me down, but i believe that this work wasn't even expected to commence in 2024, but later, but we have got to the stage where it is now ready for development, hence the call for the funding.

3. Do i consider that there is an issue with the test that had forced a change of priority? Absolutely not, as that would make no sense whatsoever. If we have an issue with the test, then the logical thing to do would be sort out that issue before bowling straight into another unknown.

Where do i believe we are?.....

In my opinion (and that's all it is) we have been told that excellent progress has been made, and the kit has been honed and tuned ready to get it out. My take on that, is that the next steps are out of our control and it is now Corepath/Behnke that are in the driving seat. This period of perceived inactivity is therefore the ideal time to bring forward future projects.

Take it as you wish, but as i say, i am not here to deceive, or give false information. Just an honest opinion as i see it.

Neil

Hi Vincentvega

They did respond to my email this morning.

Some of my questions were too specific, and further updates will need to be covered by formal announcements.

However, one of the questions did illicit the following response which i have persmission to post:

"The proceeds of the fund raise are to ACCELERATE the company’s plans and this raise does not conflict with what Allan has previously stated. The shares issued only account for 4.58% of the share capital, far less than the typical spread on the shares, so I would hope that investors would recognise this very modest level of dilution is appropriate to help the company achieve its goals FASTER."

I pointed out in my post yesterday, what i thought was the key sentence of that RNS -

"Commence development of its Point Of Care rapid test for use doctors offices and pharmacies....."

There is your answer. Things are going so well that we have moved on, and now developing this next test. Lets be honest, i don't think anyone expected to be at that stage for a long time yet?

So it looks like there is lots of significant news to come, but they won't just tell me, it will need to be officially released.

Neil

Am i wrong though Widglide?

Who approached who for the additional funding?

Why were the new and existing funders that were happy to pay more for their shares than they did last time, and why?

One standout sentence....."Commence development of its Point Of Care rapid test for use doctors offices and pharmacies....."

Someone must be very confident in the test if they are embarking on the next phase of developing that route to market. Think you will find that little nugget was aimed specifically at USA

PS for what it is worth, no i was not happy to see the RNS, and have fired off an email.

Neil